ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
120.445,91
0,15%
S&P 500
5.473,17
-0,25%
US Dollar vs BRL
5,4538
0,00%
Bitcoin
64.526,28
-0,45%
Brent Oil
84,975
-0,04%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Taro Pharmaceutical Industries Ltd (TARO)

  7. Taro Pharmaceutical Industries Ltd (TARO) Notícias

TARO

Taro Pharmaceutical Indu... (TARO)

Taro Pharmaceutical Industries Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:TARO
DataHoraFonteTítuloCódigoCompanhia
23/05/202409:10PR Newswire (US)Taro Shareholders Approve Merger with Sun PharmaNYSE:TAROTaro Pharmaceutical Industries Ltd
23/05/202409:01Edgar (US Regulatory)Form SC 13E3/A - Going private transaction by certain issuers: [Amend]NYSE:TAROTaro Pharmaceutical Industries Ltd
23/05/202408:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NYSE:TAROTaro Pharmaceutical Industries Ltd
20/05/202418:00Business WireTaro Provides Results for Year Ended March 31, 2024NYSE:TAROTaro Pharmaceutical Industries Ltd
15/05/202410:00Business WireTaro to Release Full Year Results on May 20, 2024NYSE:TAROTaro Pharmaceutical Industries Ltd
08/05/202410:07Business WireLeading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma MergerNYSE:TAROTaro Pharmaceutical Industries Ltd
15/04/202409:00Business WireTaro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.NYSE:TAROTaro Pharmaceutical Industries Ltd
15/02/202410:36Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNYSE:TAROTaro Pharmaceutical Industries Ltd
30/01/202415:18PR Newswire (US)Kuehn Law Encourages PGTI, TAST, TARO, and ANSS Investors to Contact Law FirmNYSE:TAROTaro Pharmaceutical Industries Ltd
30/01/202409:00PR Newswire (US)Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for TaroNYSE:TAROTaro Pharmaceutical Industries Ltd
25/01/202419:06Business WireTaro Provides Results for December 31, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
19/01/202418:15Business WireTaro to Release Third Quarter Results on January 25, 2024NYSE:TAROTaro Pharmaceutical Industries Ltd
17/01/202418:35Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NYSE:TAROTaro Pharmaceutical Industries Ltd
17/01/202418:30PR Newswire (US)Taro Announces Merger Agreement with Sun PharmaNYSE:TAROTaro Pharmaceutical Industries Ltd
26/10/202318:00Business WireTaro Provides Results for September 30, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
19/10/202317:30Business WireTaro to Release Second Quarter Results on October 26, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
26/07/202321:36Business WireTaro Provides Results for the Quarter Ended June 30, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
19/07/202317:00Business WireTaro to Release First Quarter Results on July 26, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
19/07/202308:00PR Newswire (US)Krensavage Asset Management Opposes Sun's Lowball Bid for TaroNYSE:TAROTaro Pharmaceutical Industries Ltd
30/06/202310:00Business WireTaro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
29/06/202317:32Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NYSE:TAROTaro Pharmaceutical Industries Ltd
28/06/202318:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NYSE:TAROTaro Pharmaceutical Industries Ltd
26/05/202318:03Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NYSE:TAROTaro Pharmaceutical Industries Ltd
23/05/202320:00Business WireTaro Provides Results for Year Ended March 31, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
18/05/202317:46Business WireTaro to Release Full Year Results on May 23, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
24/01/202319:43Business WireTaro Provides Results for December 31, 2022NYSE:TAROTaro Pharmaceutical Industries Ltd
19/01/202319:02Business WireTaro to Release Third Quarter Results on January 24, 2023NYSE:TAROTaro Pharmaceutical Industries Ltd
27/10/202219:39Business WireTaro Provides Results for September 30, 2022NYSE:TAROTaro Pharmaceutical Industries Ltd
24/10/202213:37Business WireTaro to Release Second Quarter Results on October 27, 2022NYSE:TAROTaro Pharmaceutical Industries Ltd
15/08/202207:35TipRanksH.C. Wainwright Keeps Their Buy Rating on Taro Pharmaceutical (TARO)NYSE:TAROTaro Pharmaceutical Industries Ltd
 Apresentando as notícias mais relevantes sobre:NYSE:TARO

Seu Histórico Recente

USOTC
AISNF
Asian Terminals (GM)
TG
A1QA
Albania
BIT
P1TM05
BNP Paribas Issuance
BMF
VF2N24C000700
VF2N24C000700 - 07/2024
LSE
50DN
Wells Fargo 24
EU
CMAPX
Credit Mutuel Arkea null
USOTC
OEGFF
ONEnergy (GM)
BIT
P20CO8
NLBNPIT20CO8 20240621 700
BIT
UB514M
Unicredit Bank
LSE
FIN
Finseta
TG
A2LQSN
Kreditanstalt fur Wieder...
LSE
45RD
Perm Mast A1 42
USOTC
RAMMF
RAMM Pharma (PK)
BIT
UC7A86
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados